| Comparison 6. IV ceftazidime + IV tobramycin versus oral ciprofloxacin for pulmonary exacerbations with P aeruginosa | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Oral ciprofloxacin | IV ceftazidime + IV tobramycin | |||||
| Eradication of P aeruginosa Follow-up: 2 weeks | 245 per 1000 | 624 per 1000 (365 to 1000) | RR 2.55 (1.49 to 4.39) | 89 (Richard 1997) | ⊕⊕⊕⊝ moderate1 | |
| Adverse effects - Treatment-related events Follow-up: 2 weeks | 164 per 1000 | 188 per 1000 (83 to 427) | RR 1.15 (0.51 to 2.61) | 108 (Richard 1997) | ⊕⊝⊝⊝ very low1,2 | |
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; IV: intravenous; RR: risk ratio
The quality of the evidence was downgraded by 1 due to no blinding.
The quality of the evidence was downgraded by 2 as 95% CI crossed 2 default MIDs.
From: 9, Pulmonary monitoring, assessment and management
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.